These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26858798)

  • 1. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.
    Katsuyama H; Hamasaki H; Adachi H; Moriyama S; Kawaguchi A; Sako A; Mishima S; Yanai H
    J Clin Med Res; 2016 Mar; 8(3):237-43. PubMed ID: 26858798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.
    Yanai H; Hakoshima M; Adachi H; Kawaguchi A; Waragai Y; Harigae T; Masui Y; Kakuta K; Hamasaki H; Katsuyama H; Kaga T; Sako A
    J Clin Med Res; 2017 Jul; 9(7):605-612. PubMed ID: 28611861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study.
    Itani T; Ishihara T
    Obes Sci Pract; 2018 Oct; 4(5):477-482. PubMed ID: 30338118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.
    Wang Y; Hu X; Liu X; Wang Z
    Ther Clin Risk Manag; 2016; 12():1113-31. PubMed ID: 27486328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.
    Bashier A; Khalifa AA; Rashid F; Abdelgadir EI; Al Qaysi AA; Ali R; Eltinay A; Nafach J; Alsayyah F; Alawadi F
    J Clin Med Res; 2017 Jun; 9(6):499-507. PubMed ID: 28496550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.
    Hong AR; Koo BK; Kim SW; Yi KH; Moon MK
    Diabetes Metab J; 2019 Oct; 43(5):590-606. PubMed ID: 30877709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
    Simes BC; MacGregor GG
    Diabetes Metab Syndr Obes; 2019; 12():2125-2136. PubMed ID: 31686884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
    Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Sakai K; Murohara T; Ajioka M
    Geriatr Gerontol Int; 2018 Jan; 18(1):108-114. PubMed ID: 28861952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes.
    Yokouchi G; Horio T; Matsumoto N; Fukuda K; Yoshimura R; Fujiwara R; Matsuoka Y; Sakamoto Y; Iwashima Y; Oshiro Y; Fujimoto K; Kasayuki N
    Int J Cardiol Heart Vasc; 2022 Dec; 43():101152. PubMed ID: 36457725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
    Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
    J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes.
    Kamijo Y; Ishii H; Yamamoto T; Kobayashi K; Asano H; Miake S; Kanda E; Urata H; Yoshida M
    Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419866811. PubMed ID: 31452606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis.
    Li J; Shao YH; Wang XG; Gong Y; Li C; Lu Y
    Endocr J; 2018 Mar; 65(3):335-344. PubMed ID: 29375082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.